Review





Similar Products

formyl peptide receptor 2 fpr2 antagonist wrw4  (MedChemExpress)
93
MedChemExpress formyl peptide receptor 2 fpr2 antagonist wrw4
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
Formyl Peptide Receptor 2 Fpr2 Antagonist Wrw4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/formyl peptide receptor 2 fpr2 antagonist wrw4/product/MedChemExpress
Average 93 stars, based on 1 article reviews
formyl peptide receptor 2 fpr2 antagonist wrw4 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
non peptide v1a antagonists  (Sanofi)
86
Sanofi non peptide v1a antagonists
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
Non Peptide V1a Antagonists, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non peptide v1a antagonists/product/Sanofi
Average 86 stars, based on 1 article reviews
non peptide v1a antagonists - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
c jun selective antagonist c jun peptide  (MedChemExpress)
94
MedChemExpress c jun selective antagonist c jun peptide
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
C Jun Selective Antagonist C Jun Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c jun selective antagonist c jun peptide/product/MedChemExpress
Average 94 stars, based on 1 article reviews
c jun selective antagonist c jun peptide - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
α5β1 antagonist peptide atn 161  (Selleck Chemicals)
93
Selleck Chemicals α5β1 antagonist peptide atn 161
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
α5β1 Antagonist Peptide Atn 161, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α5β1 antagonist peptide atn 161/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
α5β1 antagonist peptide atn 161 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
rage antagonist peptide25  (Tocris)
94
Tocris rage antagonist peptide25
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
Rage Antagonist Peptide25, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rage antagonist peptide25/product/Tocris
Average 94 stars, based on 1 article reviews
rage antagonist peptide25 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
non peptide antagonist  (Selleck Chemicals)
93
Selleck Chemicals non peptide antagonist
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
Non Peptide Antagonist, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non peptide antagonist/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
non peptide antagonist - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
peptide vip receptor antagonist sequences  (Creative Biolabs)
86
Creative Biolabs peptide vip receptor antagonist sequences
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
Peptide Vip Receptor Antagonist Sequences, supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptide vip receptor antagonist sequences/product/Creative Biolabs
Average 86 stars, based on 1 article reviews
peptide vip receptor antagonist sequences - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
lepr antagonist peptide allo aca  (MedChemExpress)
94
MedChemExpress lepr antagonist peptide allo aca
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
Lepr Antagonist Peptide Allo Aca, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lepr antagonist peptide allo aca/product/MedChemExpress
Average 94 stars, based on 1 article reviews
lepr antagonist peptide allo aca - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
ir specific peptide antagonist s961  (Novo Nordisk)
86
Novo Nordisk ir specific peptide antagonist s961
Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), <t>WRW4</t> <t>(Fpr2</t> antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.
Ir Specific Peptide Antagonist S961, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ir specific peptide antagonist s961/product/Novo Nordisk
Average 86 stars, based on 1 article reviews
ir specific peptide antagonist s961 - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), WRW4 (Fpr2 antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.

Journal: Frontiers in Immunology

Article Title: Fumarate inhibits the formation of neutrophil extracellular traps (NETs) in a Nrf2-controlled and Annexin-A1-dependent manner associated with mitochondrial fusion

doi: 10.3389/fimmu.2026.1770063

Figure Lengend Snippet: Expression of Nrf2 and ANXA1 in relation to NET release by neutrophils treated with dimethyl fumarate. Neutrophils isolated from mice were either pre-treated with DMF (25 µM), ML385 (Nrf2 inhibitor), WRW4 (Fpr2 antagonist) for 1 h or their combination: DMF→ML385, WRW4→DMF incubated with lipopolysaccharide (LPS) at a concentration of 50 μg/mL (for 6 h) or left unstimulated (CTR). (A) Quantification of Nrf2 expression and (B) NETs (extDNA and citH3) quantification after Nrf2 inhibition. (Ci) Representative images and (Cii) area of NETs formed upon the above treatments with WRW4 and DMF. ExtDNA is shown in green and citH3 is shown in red. To visualize co-localization of extDNA with citH3 expression, the images from each channel were overlaid. (D) Levels of ANXA1 were measured in neutrophils supernatants upon the above treatments with DMF and ML385 by ELISA. The results are expressed as the mean values ± SD; n≥3. Values significantly different between the groups (p < 0.05) according to one-way ANOVA ( post hoc Bonferroni test) are designated by letters, where the same letter indicates no differences between groups (different letters indicate statistical differences). Explanation of abbreviations: Nrf2, nuclear factor erythroid 2-related factor 2; ANXA1, Annexin A1; extDNA, extracellular DNA; citH3, citrullinated histone H3.

Article Snippet: The following inhibitors were used: nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor – ML385 (10 μM, MedChemExpress), formyl peptide receptor 2 (Fpr2) antagonist - WRW4 (10 μM, MedChemExpress), NADPH oxidase (NOX) inhibitor - Diphenyleneiodonium chloride (DPI, 10 μM, Merck), necroptosis inhibitor - Necrostatin-1 (50 μM, Torcis Bioscence, Bristol, UK), pyroptosis inhibitor - Disulfiram (30 μM, MedChemExpress) and mitochondrial complex I inhibitor - Rotenone (5 μM, Sigma-Aldrich, Saint Louis, MO, USA).

Techniques: Expressing, Isolation, Incubation, Concentration Assay, Inhibition, Enzyme-linked Immunosorbent Assay